Clinical Study Results
1. Study Name
What does this summary cover?
This summary shows the main results from one clinical study. The results are only for
this study. Other studies may find different results. Researchers and health authorities
look at the results of many studies to decide which medicines work best and are safest
for patients.
Title of the Study: A Randomized, Double-Blind, Phase 3 Study of ABP 501
Efficacy and Safety Compared to Adalimumab in Subjects
with Moderate to Severe Rheumatoid Arthritis
Brief Title: How Did ABP 501 Compare to Adalimumab in Improving
Symptoms of Rheumatoid Arthritis? devorppA
Protocol Number: 20120262
EU Trial Number: 2013-000525-31
Other Identifiers NCT01970475
(ClinicalTrials.gov):
Date of This Summary: 08 October 2018
2. Who Sponsored This Study?
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 USA
Phone (United States): +1 805-447-1000
Amgen Inc. is the sponsor of the study and manufactured ABP 501, the investigational
medicine in this study. Amgen would like to thank everyone who participated in this
study and feels it is important to share the results of this study.
1